A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Adults With Treatment-Resistant Migraine - the CONQUER Study
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 08 Feb 2019
At a glance
- Drugs Galcanezumab (Primary)
- Indications Migraine
- Focus Registrational; Therapeutic Use
- Acronyms CONQUER
- Sponsors Eli Lilly and Company
- 04 Feb 2019 Planned End Date changed from 31 Oct 2019 to 6 Oct 2019.
- 04 Feb 2019 Planned primary completion date changed from 10 Jul 2019 to 2 Jul 2019.
- 30 Jan 2019 Status changed from recruiting to active, no longer recruiting.